Efavirenz/emtricitabine/tenofovir

Efavirenz/emtricitabine/tenofovir disoproxil
Combination of
Efavirenznon-nucleoside reverse transcriptase inhibitor
Emtricitabinenucleoside analog reverse transcriptase inhibitor
Tenofovir disoproxilnucleotide analog reverse transcriptase inhibitor
Clinical data
Trade namesAtripla, Viraday, others
Other namestenofovir disoproxil fumarate/emtricitabine/efavirenz
AHFS/Drugs.comProfessional Drug Facts
License data
Pregnancy
category
Routes of
administration		By mouth
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)[1]
  • UK: POM (Prescription only)[4]
  • US: WARNING[3]Rx-only[5]
  • EU: Rx-only[6]
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
ChemSpider
  • none
KEGG
  (verify)

Efavirenz/emtricitabine/tenofovir, sold under the brand name Atripla among others, is a fixed-dose combination antiretroviral medication used to treat HIV/AIDS.[7][6] It contains efavirenz, emtricitabine, and tenofovir disoproxil.[7][6] It can be used by itself or together with other antiretroviral medications.[7] It is taken by mouth.[5][6][7]

Common side effects include headache, trouble sleeping, sleepiness, and unsteadiness.[5] Serious side effects may include high blood lactate levels, psychiatric symptoms, and enlargement of the liver.[5] It should not be used in children.[7] If used during the first trimester of pregnancy harm to the baby may occur.[5]

Efavirenz/emtricitabine/tenofovir was approved for medical use in the United States in 2006,[5][8] and in the European Union in 2007.[6] It is on the World Health Organization's List of Essential Medicines.[9] Efavirenz/emtricitabine/tenofovir is available as a generic medication.[10][11]

  1. ^ a b "TGA eBS - Product and Consumer Medicine Information Licence".
  2. ^ "Efavirenz / emtricitabine / tenofovir (Atripla) Use During Pregnancy". Drugs.com. 27 July 2018. Retrieved 31 March 2020.
  3. ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
  4. ^ "Atripla 600 mg/200 mg/245 mg film coated tablets - Summary of Product Characteristics (SmPC)". (emc). 2 March 2020. Archived from the original on 10 August 2020. Retrieved 31 March 2020.
  5. ^ a b c d e f Cite error: The named reference Atripla FDA label was invoked but never defined (see the help page).
  6. ^ a b c d e "Atripla EPAR". European Medicines Agency (EMA). 7 July 2008. Retrieved 31 March 2020.
  7. ^ a b c d e World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. p. 160. hdl:10665/44053. ISBN 9789241547659.
  8. ^ "Drug Approval Package: Atripla (Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate) NDA #021937". U.S. Food and Drug Administration (FDA). 13 December 2006. Retrieved 25 September 2021.
  9. ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  10. ^ "Office of Generic Drugs 2018 Annual Report". U.S. Food and Drug Administration (FDA). 28 January 2021. Retrieved 25 September 2021.
  11. ^ "Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 25 September 2021.